Shengshi Taikang Wins Jiangsu Province's "Double Yellow Egg" for Innovation and Entrepreneurship Talent

In Jiangxi province, as Xiao Man arrives, the warmth stirs the grasshoppers to life. Recently, 2024 Jiangsu Province, Year “ Double Innovation Program ” The selection results have been officially announced. Shengshi Taikang's talent team proudly secured a "double win": the core team led by Chief Scientific Officer Dr. Wang Tong has successfully been selected. 2024 Jiangsu Province's "Double Innovation Team" is the only "Innovation Team" in Suzhou specializing in the biopharmaceutical sector; Chief Medical Officer Dr. Zhao Jiahong has successfully been selected. 2024 Jiangsu Province's "Double Innovation Talent" of the Year.

Jiangsu Province's "Double Innovation Plan" focuses primarily on attracting and funding urgently needed, cutting-edge talent in fields such as "high-end, sophisticated, specialized, and critical" areas, as well as technologies that address key bottlenecks. It also supports the development of groundbreaking new technologies in priority sectors, making it a flagship initiative for Jiangsu's talent strategy. Centered around the province's key industries prioritized for growth, the program has played a vital role in enhancing independent innovation capabilities, driving industrial structure optimization and upgrading, and accelerating economic development.

Dr. Wang Tong, who was recently awarded Jiangsu Province’s "Double Innovation Talent" award last year, has once again led his company’s core team to earn the prestigious title of "Jiangsu Province’s Double Innovation Team," further highlighting the organization’s unwavering commitment to innovation and talent development. As Chief Scientific Officer at Shengshi Taikang, Dr. Wang brings over two decades of comprehensive experience in drug discovery and development, spanning the entire R&D and management lifecycle—from cutting-edge research to commercialization—across top-tier U.S. pharmaceutical companies and leading research institutions. A strategic scientist with a proven track record of breaking through critical technological barriers, pioneering emerging disciplines, and driving advancements in the biopharmaceutical industry, Dr. Wang has also earned recognition as a science and technology leader at multiple levels since joining Shengshi Taikang. His innovative mindset and state-of-the-art technical expertise have not only infused the company with fresh perspectives but have also enabled the establishment of a robust, integrated platform for new drug development and industrialization. Under his guidance, the company’s R&D team is rapidly advancing its pipeline of promising drug candidates, with the company’s flagship product—a novel class-II antidiabetic drug called Senglitin—already successfully launched and available on the market.

Dr. Zhao Jiahong, a core member of the "Innovation and Entrepreneurship Team," also received the prestigious Jiangsu Province "Innovation and Entrepreneurship Talent" honor this time. As Chief Medical Officer at Shengshi Taikang, Dr. Zhao brings over 20 years of experience in drug clinical trials and team management, and serves as an external expert for the CDE. He boasts extensive hands-on expertise in medical affairs, early-stage drug development, clinical development strategies, and international multi-center clinical trials—having led or contributed to more than 600 clinical projects. Additionally, he has deep insights into post-marketing drug reevaluation efforts. Since joining Shengshi Taikang, Dr. Zhao has taken full responsibility for overseeing the company’s critical initiatives, including new drug clinical development strategies, pathways, and post-launch expansion studies.

Among the core members of the "Innovation and Entrepreneurship Team," Dr. Lu Qin earned her PhD in Systems Biology of Medicine from Fudan University and holds an associate senior professional title. She has made significant contributions to research in the biological sciences, publishing numerous high-quality papers and receiving nearly 10 Holds an authorized invention patent and has led the company's bio team to successfully tackle multiple challenging projects, earning numerous prestigious awards, including the Park Leader distinction. Dr. Ou Yang Zhenwu earned his PhD in Organic Chemistry from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of medicinal chemistry, having published in internationally renowned chemistry journals. 6 A high-quality paper showcasing his profound expertise in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly leveraged "innovative synthetic methodologies" to streamline synthesis routes, significantly enhancing the efficiency of new drug screening while also helping the company cut costs in its drug development efforts.

Shengshi Taiko, a biotechnology company in the commercialization phase, is led by an innovative team of experts with decades of international experience spanning the entire lifecycle of pharmaceutical products. The company is dedicated to the research, development, and industrialization of high-quality, differentiated small-molecule innovative drugs. Leveraging its integrated drug R&D technology platform and diverse business insights, Shengshi Taiko has built a robust pipeline of cutting-edge therapies targeting areas such as blood sugar management, cancer treatment, and autoimmune diseases.